|Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning|
MA Shipp, KN Ross, P Tamayo, AP Weng, JL Kutok, RCT Aguiar, ...
Nature medicine 8 (1), 68-74, 2002
|Age-related clonal hematopoiesis associated with adverse outcomes|
S Jaiswal, P Fontanillas, J Flannick, A Manning, PV Grauman, BG Mar, ...
New England Journal of Medicine 371 (26), 2488-2498, 2014
|Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl|
E Weisberg, PW Manley, W Breitenstein, J Brüggen, SW Cowan-Jacob, ...
Cancer cell 7 (2), 129-141, 2005
|Clinical effect of point mutations in myelodysplastic syndromes|
R Bejar, K Stevenson, O Abdel-Wahab, N Galili, B Nilsson, ...
New England Journal of Medicine 364 (26), 2496-2506, 2011
|An immunogenic personal neoantigen vaccine for patients with melanoma|
PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, ...
Nature 547 (7662), 217-221, 2017
|Evolution and impact of subclonal mutations in chronic lymphocytic leukemia|
DA Landau, SL Carter, P Stojanov, A McKenna, K Stevenson, ...
Cell 152 (4), 714-726, 2013
|Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia|
AA Ferrando, DS Neuberg, J Staunton, ML Loh, C Huard, SC Raimondi, ...
Cancer cell 1 (1), 75-87, 2002
|SF3B1 and other novel cancer genes in chronic lymphocytic leukemia|
L Wang, MS Lawrence, Y Wan, P Stojanov, C Sougnez, K Stevenson, ...
New England Journal of Medicine 365 (26), 2497-2506, 2011
|ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia|
LZ Rassenti, L Huynh, TL Toy, L Chen, MJ Keating, JG Gribben, ...
New England Journal of Medicine 351 (9), 893-901, 2004
|Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and …|
MR Green, S Monti, SJ Rodig, P Juszczynski, T Currie, E O'Donnell, ...
Blood, The Journal of the American Society of Hematology 116 (17), 3268-3277, 2010
|Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease|
S Jaiswal, P Natarajan, AJ Silver, CJ Gibson, AG Bick, E Shvartz, ...
New England Journal of Medicine 377 (2), 111-121, 2017
|The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma|
KJ Savage, S Monti, JL Kutok, G Cattoretti, D Neuberg, L De Leval, ...
Blood 102 (12), 3871-3879, 2003
|NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth|
T Palomero, WK Lim, DT Odom, ML Sulis, PJ Real, A Margolin, ...
Proceedings of the National Academy of Sciences 103 (48), 18261-18266, 2006
|Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response|
S Monti, KJ Savage, JL Kutok, F Feuerhake, P Kurtin, M Mihm, B Wu, ...
Blood 105 (5), 1851-1861, 2005
|Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma|
JG Gribben, AS Freedman, D Neuberg, DC Roy, KW Blake, SD Woo, ...
New England Journal of Medicine 325 (22), 1525-1533, 1991
|Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)|
GW Sledge, D Neuberg, P Bernardo, JN Ingle, S Martino, EK Rowinsky, ...
Journal of Clinical Oncology 21 (4), 588-592, 2003
|Mutations driving CLL and their evolution in progression and relapse|
DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ...
Nature 526 (7574), 525-530, 2015
|Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412|
RM Stone, DJ DeAngelo, V Klimek, I Galinsky, E Estey, SD Nimer, ...
Blood 105 (1), 54-60, 2005
|Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.|
AJ Nixon, D Neuberg, DF Hayes, R Gelman, JL Connolly, S Schnitt, ...
Journal of clinical oncology 12 (5), 888-894, 1994
|Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients|
FS Hodi, M Butler, DA Oble, MV Seiden, FG Haluska, A Kruse, S MacRae, ...
Proceedings of the National Academy of Sciences 105 (8), 3005-3010, 2008